OTP-01 (Jankistomig)
Cancers known to benefit from PD-1 and/or VEGF treatment (e.g., solid tumors)
Phase 1/2aActive
Key Facts
Indication
Cancers known to benefit from PD-1 and/or VEGF treatment (e.g., solid tumors)
Phase
Phase 1/2a
Status
Active
Company
About Ottimo Pharma
Ottimo Pharma is a UK-based, private, clinical-stage biotech focused on innovative immuno-oncology therapeutics. Its core technology is a platform for developing dual-paratopic antibodies, with a lead asset, OTP-01 (Jankistomig), targeting PD-1 and VEGFR2 simultaneously in a single agent. The company has strong leadership with deep industry experience from companies like Seagen, Novartis, and Pfizer, and has achieved key milestones including FDA IND clearance and first patient dosing in a Phase I/IIa study. Ottimo is positioned to address a significant unmet need in cancers responsive to PD-1 and VEGF pathway inhibition.
View full company profile